about
sameAs
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.Legionnaires' disease in immunocompromised patients: a case report of Legionella longbeachae pneumonia and review of the literature.Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantation.Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes.Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats.The first recombinant FVIII produced in human cells--an update on its clinical development programme.Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges.Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.The use of recombinant activated factor VII in patients with acquired haemophilia.Half-life extended factor VIII for the treatment of hemophilia A.Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH).Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland.Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.Characterisation of the enzymatic complex for the first step in glycosylphosphatidylinositol biosynthesis.siRNA mediated knockdown of tissue factor expression in pigs for xenotransplantation.Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans.Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin.Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia.DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders.Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.Effect of TNF-alpha blockade on coagulopathy and endothelial cell activation in xenoperfused porcine kidneys.Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.Diagnosis and treatment of acquired von Willebrand syndrome.Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and O
P50
Q33378351-76228646-471E-4A94-8BDA-D68B19D769D9Q33378697-E6A3EF9F-FDAE-48A5-A53C-096BC2CDA352Q33415141-8792CA08-279B-4A29-8262-384A46AE67C7Q33672095-F3B96BB0-1777-4262-9AE9-F31FA67CCC6BQ35080086-C96BF233-F4F6-4443-A5FA-F4C12B521920Q36250920-E8293B48-3583-4F70-B5DC-8518052C22A5Q38136977-42B87928-EF74-4C05-BE42-36EB005C9C8DQ38170563-55BE1EB8-B9F3-4FB2-914C-62F63F2672CFQ38258486-9C95E49D-4CB0-434A-B80B-1FA3DA60FF70Q38282775-2FCFDFBE-DC05-41B3-8012-0D3505F72B2FQ38527501-FB5B4144-DFC8-4195-A141-AFC60E0433E0Q38543286-42B2BAF9-F76C-4CBE-92B3-A8652E7FB2C1Q38588576-9B40E6B2-0A1B-4D46-8625-07D7AAC40D35Q38705742-067F09CB-BCBE-468A-B5D2-9B516A636F68Q38715833-64568655-E4EF-4366-B538-0DDD503123E0Q38818573-9C6C3538-715B-40E7-98BA-F77465DD6B6EQ38944641-71C41F96-B329-4A09-9104-723E82804F23Q38965273-EEDD50F2-4350-4925-8CDC-504C8F4C5676Q39970914-760BCD9F-6997-441F-ADDD-07A4894431D2Q40018362-56BCDF16-3AD6-4C5F-8A62-CD61DA417F52Q40632785-B58AF0FE-75AA-4540-AEDB-4FFD6A480815Q40893953-BAD3BA5E-B111-4D0A-AF2C-064714E15DB6Q41161110-F5992078-5D4F-46C2-AB34-F14DB1850E92Q41681553-9D007540-91F6-4DBB-BAB7-F4F69E34D525Q42958772-0DE2BE54-9D6E-4B9A-981C-E980F4C2C243Q45238676-C7B34FC1-6CCB-41EB-9C45-4194D6599007Q45868800-9747DF8D-384B-42F4-A33E-03C99B0D9FA9Q45869314-E3839583-76F9-4FF3-9710-B94EF6C891BFQ45871601-3A2509B6-EF00-4A04-98F8-A6FB51504A6CQ45871901-CACF72EE-E2E3-4DCA-A5D8-1D79A2AB6CA9Q45877097-49D75444-8FE8-4D3D-8B1C-7AF5014F2C5FQ45883402-A8020D7B-D8F4-4AA4-A797-7CFB562C0B70Q45883773-F716FA93-24C3-45C8-86FC-57BA5C812E64Q45884927-351A9593-D5A2-4F9F-9EA4-B6E3B451FBFCQ45887360-DAFCB26D-56F2-4438-A9F4-EB1295B01162Q47670138-A599A608-94EC-4B11-A498-4E577BCB4C61Q50692146-B9470208-7FEB-4E99-BF1B-2648C3ACD896Q50717712-67BCA0A0-630E-4430-AA32-492B43B34842Q51250156-B377F3B1-51D7-416D-8E04-C9F9A5E2FC27Q56960816-5E0F8238-A466-4FC7-8799-D59868DA4B4E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
A Tiede
@ast
A Tiede
@en
A Tiede
@es
A Tiede
@nl
type
label
A Tiede
@ast
A Tiede
@en
A Tiede
@es
A Tiede
@nl
altLabel
Andreas Tiede
@en
prefLabel
A Tiede
@ast
A Tiede
@en
A Tiede
@es
A Tiede
@nl
P106
P1153
14720292000
P31
P496
0000-0002-3600-8536